Stock analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a research report issued on Monday. The brokerage set a “hold” rating on the stock.
Brooklyn ImmunoTherapeutics Stock Down 8.1 %
NYSE BTX opened at $0.91 on Monday. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The company has a market capitalization of $53.53 million, a PE ratio of -0.44 and a beta of 4.61. The firm’s 50 day moving average is $1.42 and its 200-day moving average is $1.75.
About Brooklyn ImmunoTherapeutics
Featured Stories
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What is Put Option Volume?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What Investors Need to Know to Beat the Market
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.